UVB phototherapy for psoriasis; reply
Koek, M.B.G.; Buskens, Erik; Bruijnzeel-Koomen, C.A.F.M.; Sigurdsson, V.

Published in:
British Medical Journal

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2009

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):

Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.
This will also allow recall of patients to monitor skin cancer if necessary.

Heather Cameron associate specialist in dermatology h.cameron@dundee.ac.uk

Robert Dawe consultant dermatologist, Photobiology Unit, Ninewells Hospital and Medical School, Dundee DD1 9SY

Competing interests: None declared.


Cite this as: BMJ 2009;338:b2213

Authors’ reply

Cameron and Dawe suggest that careful selection of patients is essential to maintain and safeguard efficacy and safety, seeming to think that patients in our trial were also specifically selected. However, our patients were a representative sample of those considered clinically eligible.

Although only 196 patients from 14 hospitals participated in our study, the type of selection Cameron and Dawe aim at was not part of our eligibility criteria. Only 325 patients were referred to us for participation in the trial. To keep a record of all of the reasons for non-referral was unfeasible, but from the few dermatologists who did keep a record we know that many patients were simply not willing to participate. Also sometimes dermatologists simply forgot to ask.

We noted that participants in our trial were people from all walks of life. Although we do not rule out that minimal selection has occurred, we are convinced that on average our participants adequately represent patients with psoriasis who receive (outpatient) UVB treatment. We therefore disagree with Cameron and Dawe because our trial and experience adequately represent patients with psoriasis.

Mayke B G Koek research fellow dermatology, University Medical Centre Utrecht, 3584 CX Utrecht, Netherlands author@koek.com

Erik Buskens professor of medical technology assessment, Department of Epidemiology, University Medical Centre Groningen, University of Groningen, Groningen, Netherlands

Carla AFM Bruijnzeel-Koomen professor of dermatology/allergology

Vigfús Sigurdsson dermatologist, University Medical Centre Utrecht, 3584 CX Utrecht, Netherlands

Competing interests: None declared.


Cite this as: BMJ 2009;338:b2215

DEPRIVATION OF LIBERTY

Liberty safeguards in hospital

The interplay of deprivation of liberty safeguards and the Mental Capacity Act is probably most complex in general hospitals. People with delirium, dementia, or severe aphasia or who are in coma will lack the capacity to consent to admission or prolonged stay because of their underlying cognitive state. Delirium and other neuropsychiatric disorders are often subject to chemical restraint in general hospitals, especially in adult critical care units. Such restraint is done in a patient’s best interest but could be regarded as deprivation of liberty under the Mental Capacity Act.

In managing a patient who has delirium in a general ward or intensive care, doctors may need to consider the use of the amended Mental Health Act 2007. However, this may not be immediately possible in an emergency—for example, the patient suddenly becoming aggressive and unmanageable. If a patient experiences repeated episodes of aggression agitation alternating with lucid intervals, repeated use of restraint is likely to amount to deprivation. The Mental Health Act 2007 could be used again, but practice may not be straightforward, especially when a hospital consultant acting in the best interest of such patients tries to ensure that they do not leave hospital before they have recovered or adequate community support has been set up. Under the act the hospital consultant has to subsume the role of responsible medical officer.

Hospital consultants need to be aware of these issues and work with their mental health
counterparts in drawing up guidelines (and perhaps protocols). Training and educational programmes for general hospital staff may also be appropriate.

Nitin Gupta consultant psychiatrist, South Staffordshire and Shropshire Healthcare NHS Foundation Trust, Margaret Stanhope Centre, Burton on Trent DE13 0RB nitinguptase59@yahoo.co.in

Competing interests: None declared.


Cite this as: BMJ 2009;338:b2430

US HEALTHCARE REFORM

Choice and equality in health

The US aversion to a single payer system highlights a fundamental difference in mentality between the United States and the United Kingdom that the US government would do well to remember. To many Americans the term single payer represents socialised medicine and government bureaucracy, while in the NHS it represents a noble ideal of use according to need but contribution according to the ability to pay. The US healthcare system is driven by the desire for choice whereas the NHS is driven by the desire for equality.

In moving to empower NHS patients with choice, the UK government is in danger of sacrificing the principle of equality on which the service was founded, for choice and equality necessarily conflict. If choice is possible then, by definition, differences exist in the quality of care being provided in the NHS and some are receiving a substandard service that an informed patient would not choose. Allowing patient choice by publicly reporting outcomes is likely to exacerbate inequality as some are better positioned to exercise choice—most likely rich and well educated people.

These people are more likely to be politically active, and thus promoting choice seems an effective way of scoring political points in the guise of making the NHS fairer. The fairest approach is to foster a system in which choice is not needed by dealing with those whom no informed patient would choose.

Adam M Ali Frank Knox fellow, Harvard University, Cambridge, MA 02138, USA adamali@fas.harvard.edu

Competing interests: None declared.

1 Rohrer B. Senate finance chairman sees progress on US healthcare reform. BMJ 2009; 338:b2134. (26 May)

Cite this as: BMJ 2009;338:b2423

A/H1N1 flu

NSAIDs and flu

The potentially harmful effects of non-steroidal anti-inflammatory drugs (NSAIDs) are rarely discussed in the treatment of A/H1N1 flu, which has caused high death rates in Mexico.1,2 Severe and fatal cases, including sudden death, are characterised by severe sepsis with multi-organ failure with findings such as fever, leucocytosis, leucopenia, acute respiratory distress syndrome (ARDS), liver impairment, renal failure, rhabdomyolysis, and hypotension.3 NSAIDs may aggravate these syndromes, leading to multi-organ failure.3

Since the flu pandemics of the 20th century salicylates have been linked to Reye’s syndrome and their use restricted in children. But NSAIDs such as diclofenac, mefenamic acid, and ibuprofen are still used as antipyretics in many countries, albeit less often than aspirin. Since the use of diclofenac and mefenamic acid was restricted in children in Japan in 2000, the case fatality of so called flu associated encephalopathy has fallen dramatically.4

Reanalysing the World Health Organization’s data on A/H1N1 flu,2 I found that the odds ratio of case fatality in adults (3.7%) and children and adolescents under 20 (0.5%) is 7.63 (95% confidence interval 3.78 to 15.85, P<0.001). Whether the people who died were treated with NSAIDs is not known. However, NSAIDs are readily available over the counter in Mexico and people commonly self treat.5

Case-control studies are urgently required to assess the risks of NSAIDs as antipyretics in flu.

Rokuro Hama chariperson, Japan Institute of Pharmacovigilance, 902 Ueshono-2-17, Tennoji-ku Osaka, Japan 543-0002 geex00724@msnifty.com

Cite this as: BMJ 2009;338:b2345

Aspirin in the 1918 pandemic

Aspirin may have enhanced the virulence of the flu virus in the 1918 pandemic, which has implications for A/H1N1 flu.1 During the 18 months of the 1918-9 pandemic, 27 million people died worldwide, mortality being highest in the second wave, October 1918, especially in the United States. Age specific mortality followed a W curve, with high death rates in healthy young adults aged 20-40 as well as in children under 5 years old and people aged 65 and over. It was wartime and young men were crowded together in military camps, but the mortality was also high in men of the same age who remained at home.2

In September 1918 Rupert Blue, the US surgeon general, advised that flu could be controlled “only by intelligent action of the public.” He added: “During the present outbreak in foreign countries, the salts of quinine and aspirin have been most generally used during the acute attack, those of aspirin apparently with much success in the relief of the symptoms.”3

To subdue fever 5-10 grains (324-648 mg) of aspirin tablets could be prescribed every three hours up to 7 g in 24 hours.4 According to the same commentator on homeopathic medicine, mortality was 1% or less without aspirin and 5-30% in patients treated with aspirin in hospitals or in the armed forces.4

Tsunetoshi Shimazu director, Shimazu Clinic 31 Higashitakada-chodai, Mibu, Nakagyo-ku, Kyoto, Japan 604-8845 shimazu-clinic@giga.ocn.ne.jp

Competing interests: None declared.

1 O’Dowd A. Number of confirmed A/H1N1 flu cases doubles over one weekend. BMJ 2009; 338:b1962. (12 May.)

Cite this as: BMJ 2009;338:b2345